We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+24.43%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.3B
AUM Growth
-$343M
Cap. Flow
-$2.51B
Cap. Flow %
-18.9%
Top 10 Hldgs %
48.31%
Holding
117
New
19
Increased
28
Reduced
28
Closed
22

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$737M
2
SPGI icon
S&P Global
SPGI
+$177M
3
SHW icon
Sherwin-Williams
SHW
+$160M
4
WCG
Wellcare Health Plans, Inc.
WCG
+$145M
5
GG
Goldcorp Inc
GG
+$139M

Top Sells

Rank Stock Value
1
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
+$616M
2
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
+$370M
3
EQIX icon
Equinix
EQIX
+$283M
4
META icon
Meta Platforms (Facebook)
META
+$194M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$193M

Sector Composition

Rank Sector Weight
1 Healthcare 29.51%
2 Technology 21.38%
3 Communication Services 17.25%
4 Industrials 6.59%
5 Consumer Discretionary 6.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVCR icon
51
NovoCure
NVCR
$1.99B
$50.6M 0.38%
1,050,000
-200,000
-16% -$9.63M
KYNB
52
Kyntra Bio
KYNB
$30.4M
$49.8M 0.37%
36,623
+6,623
+22% +$8.98M
DIS icon
53
Walt Disney
DIS
$186B
$48.9M 0.37%
+440,000
New +$49.2M
NXPI icon
54
NXP Semiconductors
NXPI
$56.9B
$47.3M 0.36%
535,000
– –
ALNY icon
55
Alnylam Pharmaceuticals
ALNY
$31.6B
$46.7M 0.35%
500,000
-50,000
-9% -$4.18M
FATE icon
56
Fate Therapeutics
FATE
$279M
$43.9M 0.33%
2,500,000
+300,000
+14% +$4.74M
RDUS
57
DELISTED
Radius Health, Inc.
RDUS
$40.7M 0.31%
2,043,149
– –
SINA
58
DELISTED
Sina Corp
SINA
$38.5M 0.29%
+650,000
New +$39M
ARWR icon
59
Arrowhead Research
ARWR
$12.3B
$35.2M 0.27%
1,920,609
+420,609
+28% +$6.94M
CVS icon
60
CVS Health
CVS
$119B
$33.7M 0.25%
625,000
-305,000
-33% -$18.8M
RC
61
Ready Capital
RC
$311M
$32.9M 0.25%
2,243,239
+40,000
+2% +$611K
PTCT icon
62
PTC Therapeutics
PTCT
$5.83B
$26.3M 0.2%
700,000
– –
FOXA icon
63
Fox Class A
FOXA
$28.8B
$26M 0.2%
+709,220
New +$27.6M
CRSP icon
64
CRISPR Therapeutics
CRSP
$5.75B
$25.9M 0.19%
725,000
-525,000
-42% -$18.2M
STML
65
DELISTED
Stemline Therapeutics, Inc.
STML
$25.7M 0.19%
+2,000,000
New +$22.6M
CDXS icon
66
Codexis
CDXS
$183M
$25.7M 0.19%
1,250,000
+95,000
+8% +$1.85M
ZYME icon
67
Zymeworks
ZYME
$2.05B
$25.5M 0.19%
1,575,000
– –
QTNT
68
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-60,000
Closed -$21.1M
PTGX icon
69
Protagonist Therapeutics
PTGX
$9.99B
$22.5M 0.17%
1,790,000
-409,674
-19% -$3.62M
CCXI
70
DELISTED
ChemoCentryx, Inc.
CCXI
$20.8M 0.16%
1,500,000
+50,000
+3% +$572K
TECX
71
Tectonic Therapeutic
TECX
$736M
$19.8M 0.15%
75,000
+20,833
+38% +$3.81M
PGNX
72
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$19.5M 0.15%
4,200,820
– –
VYGR icon
73
Voyager Therapeutics
VYGR
$209M
$19.1M 0.14%
1,000,158
+91,000
+10% +$1.19M
SVRA icon
74
Savara
SVRA
$1.15B
$17.9M 0.13%
2,425,000
– –
BMS
75
DELISTED
Bemis
BMS
$17.5M 0.13%
316,160
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q1 2019 Portfolio in Review

As of Q1 2019, Thomas Steyer held 117 positions worth $13.3B, down 2.5% from $13.6B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Thomas Steyer withdrew a net $2.51B in Q1 2019, closing 22 positions and reducing 28 holdings. Its most notable exit was Twenty-First Century Fox, Inc. Class A, an estimated $616M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 21% a quarter earlier, followed by Technology and Communication Services.

Against the trend, Thomas Steyer opened a new position in Celgene Corp worth $795M.

  • Thomas Steyer's largest Q1 2019 buy was Celgene Corp: 8,430,000 shares worth $795M.
  • Thomas Steyer added most to Red Hat Inc in Q1 2019, an estimated $116M increase.
  • Thomas Steyer's biggest Q1 2019 reduction was Equinix, cutting an estimated $283M.
  • Thomas Steyer fully exited Twenty-First Century Fox, Inc. Class A in Q1 2019, selling an estimated $616M.
  • Thomas Steyer's ten largest holdings make up 48% of its $13.3B portfolio in Q1 2019.
  • Thomas Steyer opened 19 new positions and closed 22 in Q1 2019.
  • Thomas Steyer's portfolio value fell 2.5% quarter-over-quarter to $13.3B.

Based on Farallon Capital Management's 13F filing for Q1 2019, filed 15 May 2019.